Notably, the synergy between atezolizumab, a PD-L1 inhibitor, and bevacizumab, a VEGF inhibitor, has demonstrated promising anti-tumor efficacy and an acceptable safety profile in a phase 1b trial encompassing individuals with unresectable HCC. Here, CD274 is linked to hepatocellular carcinoma.